» Articles » PMID: 35887617

Vascular Calcification Is Associated with Fetuin-A and Cortical Bone Porosity in Stone Formers

Abstract

Background: Nephrolithiasis has been associated with bone loss and vascular calcification (VC), reflecting abnormal extraosseous calcium deposition. Fetuin-A (Fet-A) acts as a potent inhibitor of ectopic mineralization. The aim of the present study was to evaluate the prevalence of VC in stone formers (SF) and non-stone formers (NSF) and to investigate potential determinants of VC among SF, including circulating levels of Fet-A and bone microarchitecture parameters. Methods: Abdominal aortic calcification (AAC) was assessed using available computed tomography in SF and in age-, sex-, and BMI-matched NSF (potential living kidney donors). Serum Fet-A was measured in stored blood samples from SF. Bone microarchitecture parameters were obtained as a post hoc analysis of a cross-sectional cohort from young SF evaluated by high-resolution peripheral quantitative computed tomography (HR-pQCT). Results: A total of 62 SF (38.0 [28.0−45.3] years old) and 80 NSF (40.0 [37.0−45.8] years old) were included. There was no significant difference in AAC scores between SF and NSF. However, when dividing SF according to mean AAC score, below <5.8% (n = 33) or above ≥5.8% (n = 29), SF with higher AAC presented significantly higher BMI and tibial cortical porosity (Ct.Po) and significantly lower serum HDL, klotho, Fet-A, and eGFR. Urinary calcium did not differ between groups, but fractional excretion of phosphate was higher in the former. Upon multivariate regression, BMI, serum Fet-A, and tibial Ct.Po remained independently associated with AAC. Conclusions: This study suggests an association between reduced circulating Fet-A levels and increased bone Ct.Po with VC in SF.

Citing Articles

The impact of fetuin-A on predicting aortic arch calcification: secondary analysis of a community-based survey.

Lin Y, Lin M, Shi C, Lin Y, Lin C, Yang Y Front Cardiovasc Med. 2024; 11:1415438.

PMID: 39040998 PMC: 11260669. DOI: 10.3389/fcvm.2024.1415438.

References
1.
Heiss A, DuChesne A, Denecke B, Grotzinger J, Yamamoto K, Renne T . Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem. 2003; 278(15):13333-41. DOI: 10.1074/jbc.M210868200. View

2.
Ferraro P, Taylor E, Eisner B, Gambaro G, Rimm E, Mukamal K . History of kidney stones and the risk of coronary heart disease. JAMA. 2013; 310(4):408-15. PMC: 4019927. DOI: 10.1001/jama.2013.8780. View

3.
Hu M, Shiizaki K, Kuro-O M, Moe O . Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol. 2013; 75:503-33. PMC: 3770142. DOI: 10.1146/annurev-physiol-030212-183727. View

4.
Rodrigues F, Lima T, Zambrano L, Heilberg I . Dietary pattern analysis among stone formers: resemblance to a DASH-style diet. J Bras Nefrol. 2020; 42(3):338-348. PMC: 7657059. DOI: 10.1590/2175-8239-JBN-2019-0183. View

5.
Shavit L, Girfoglio D, Vijay V, Goldsmith D, Ferraro P, Moochhala S . Vascular calcification and bone mineral density in recurrent kidney stone formers. Clin J Am Soc Nephrol. 2015; 10(2):278-85. PMC: 4317743. DOI: 10.2215/CJN.06030614. View